Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 12/20 | 0.65 |
| ▸ | RARA | P10276 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.52 |
| ▸ | CTRC | Q99895 | 1/20 | 0.51 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350629 | 1.00 | RARB (0.65) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL2355261 | 0.99 | RARB (0.64) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL12243251 | 0.95 | RARB (0.63) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL2352909 | 0.95 | RARB (0.63) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL12243234 | 0.91 | RARB (0.51) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL12243111 | 0.91 | RARB (0.51) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL12243223 | 0.91 | RARB (0.51) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL2355983 | 0.90 | NPC1 (0.58) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL12243228 | 0.89 | RARB (0.50) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL8379558 | 0.89 | RAB9A (0.49) | MEN1ALDH1A1MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | RARB 2792/4885RARA 2259/4885MEN1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.